The HARMONY-EHA webinar (July 16, 2020) brought together leading specialists in the field of Acute Myeloid Leukemia (AML) to discuss HARMONY’s research projects in this area and the use of Big Data in advancing our knowledge of this blood cancer. The webinar is now available for viewing on demand.
Overview of topics discussed
An introduction to the HARMONY Alliance: outlining current HARMONY activities in AML and updates on the ongoing analysis of the AML pilot project
Lars Bullinger, Charité Berlin − HARMONY Partner and Leader of Work Package 2: Definition of Outcomes
Professor Lars Bullinger provided an overview of HARMONY and how it gathers Big Data using the HARMONY Big Data Platform in partnership with its numerous stakeholders. He went on to discuss the results of a HARMONY pilot study, which aims to use Big Data to revise treatment strategies in AML by identifying how certain gene–gene interactions influence disease progression.
Minimal Residual Disease in AML
Gert J Ossenkoppele, Amsterdam University Medical Center (VUMC) - HARMONY Partner
Professor Gert J Ossenkoppele overviewed the definition of minimal residual disease and how it can be measured in clinical practice. He explained how HARMONY is using Big Data to assess whether minimal residual activity could be used as a surrogate endpoint in clinical trials.
Data submitted by GPOH and envisioned effect of AML data coming from adults
Dirk Reinhardt, German Society for Paediatric Oncology and Haematology (GPOH) – HARMONY Partner
Professor Dirk Reinhardt discussed the pediatric AML data submitted by GPOH to the HARMONY Big Data Platform. He provided an overview of the HARMONY research project in pediatric blood cancers, which aims to identify the similarities and differences in pediatric and adult AML.
Live Q&A
Moderated by Francesco Cerisoli, Head of Research and Mentoring at the EHA
The live Q&A sessions allowed members of the audience to engage with the speakers and ask any relevant questions about HARMONY and AML. Find out the answers to these important questions by watching the webinar; follow the link at the top of the page or click here.
In June, we held a webinar in partnership with the EHA on the topic of HARMONY and COVID-19. Click here to watch it.
The HARMONY Alliance is a public-private partnership for Big Data in Hematology, established in January 2017. Our mission is to unlock and spread valuable knowledge on Hematologic Malignancies (blood cancers) among a large number of stakeholders. The ultimate goal of HARMONY is to harness and mine Big Data to speed up the development of improved treatments and treatment strategies for patients.
We currently have 53 Partners and 41 Associated Members from across 17 European countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations. The HARMONY Alliance is funded by the Innovative Medicines Initiative (IMI).
• Read more | Become involved
HARMONY takes action to manage COVID-19
• Read about the HARMONY COVID19 Data Platform | View more COVID19 activities
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
